aTyr Pharma
ATYR
47 hedge funds and large institutions have $75.1M invested in aTyr Pharma in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 17 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
8.03% more ownership
Funds ownership: 61.71% → 69.73% (+8%)
8% less capital invested
Capital invested by funds: $81.5M → $75.1M (-$6.44M)
16% less funds holding
Funds holding: 56 → 47 (-9)
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$7.82M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.49M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.74M |
| 4 |
CC
Checkpoint Capital
San Francisco,
California
|
+$870K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$630K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$1.36M |
| 2 |
Barclays
London,
United Kingdom
|
-$1.18M |
| 3 |
Goldman Sachs
New York
|
-$424K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$309K |
| 5 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
-$178K |
ATYR Hedge Fund Activity: Q2 2024 in Review
47 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2024, worth a combined $75.1M — down 7.9% from $81.5M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ATYR and 8 opened new positions — a net loss of 9 holders — while 12 trimmed existing stakes and 21 added.
The largest buyer was Federated Hermes, adding an estimated $7.82M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $1.36M sold.
- 47 institutional investors held aTyr Pharma (ATYR) as of Q2 2024, down from 56 in Q1 2024.
- Funds reported $75.1M of aTyr Pharma stock for Q2 2024, down 7.9% quarter-over-quarter.
- 8 funds opened new aTyr Pharma positions in Q2 2024 and 17 closed out, a net change of -9 holders.
- The largest aTyr Pharma buyer in Q2 2024 was Federated Hermes, an estimated $7.82M added.
- The largest aTyr Pharma seller in Q2 2024 was Octagon Capital Advisors, an estimated $1.36M sold.
Based on aggregated 13F filings for Q2 2024.